← Browse by Condition
Medical Condition

bone metastases

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for bone metastases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — bone metastases Clinical Trials

How many clinical trials are currently recruiting for bone metastases?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for bone metastases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for bone metastases?
bone metastases research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a bone metastases clinical trial?
Eligibility criteria for bone metastases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
UMC Utrecht 1 trial
Duke University 1 trial
Costantino Errani 1 trial
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 trial
Zhejiang Cancer Hospital 1 trial

Recruiting Clinical Trials

NCT02356497
Recruiting
Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort
Enrollment
2,500 pts
Location
Netherlands
Sponsor
UMC Utrecht
View Trial →
NCT03261544
Recruiting
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
Enrollment
50 pts
Location
United States
Sponsor
Duke University
View Trial →
NCT06524843
Recruiting
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
Enrollment
250 pts
Location
Italy
Sponsor
Costantino Errani
View Trial →
NCT06367491
Recruiting
National Database of Bone Metastases
Enrollment
800 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud...
View Trial →
NCT06538896 Phase 2
Recruiting
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Enrollment
20 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
View Trial →

Related Conditions

sarcoma (1) proximal femur replacement (1) triple negative breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology